John P. McLaughlin

2017

In 2017, John P. McLaughlin earned a total compensation of $3.4M as Chief Executive Officer at PDL BioPharma, a 18% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$1,490,234
Salary$717,003
Stock Awards$1,200,000
Other$10,000
Total$3,417,237

McLaughlin received $1.5M in non-equity incentive plan, accounting for 44% of the total pay in 2017.

McLaughlin also received $717K in salary, $1.2M in stock awards and $10K in other compensation.

Rankings

In 2017, John P. McLaughlin's compensation ranked 3,096th out of 14,666 executives tracked by ExecPay. In other words, McLaughlin earned more than 78.9% of executives.

ClassificationRankingPercentile
All
3,096
out of 14,666
79th
Division
Manufacturing
1,066
out of 5,772
82nd
Major group
Chemicals And Allied Products
289
out of 2,075
86th
Industry group
Drugs
220
out of 1,731
87th
Industry
Biological Products, Except Diagnostic Substances
41
out of 313
87th
Source: SEC filing on April 26, 2018.

McLaughlin's colleagues

We found five more compensation records of executives who worked with John P. McLaughlin at PDL BioPharma in 2017.

2017

Danny Hart

PDL BioPharma

Vice President, Business Development

2017

Dominique Monnet

PDL BioPharma

President

2017

Peter Garcia

PDL BioPharma

Chief Financial Officer

2017

Christopher Stone

PDL BioPharma

General Counsel

2017

Steffen Pietzke

PDL BioPharma

Chief Accounting Officer

News

You may also like